During the past decade, Azienda Ospedaliera Fatebenefratelli e Oftalmico conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" #1 sponsor was "Amaranth Medical Inc." with 2 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 2 trials sponsored, "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc." with 2 trials sponsored, "Bial - Portela C S.A." with 1 trials sponsored and "Consorzio Oncotech" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator, "Clinical Research Technology S.r.l." with 1 trials as a collaborator, "Istituto Clinico Humanitas" with 1 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 1 trials as a collaborator and "Sintesi Research Srl" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" are "Coronary Artery Disease" (2 trials), "Dravet Syndrome" (2 trials), "Heart Failure" (2 trials), "Myocardial Ischemia" (2 trials) and "Autoinflammatory Syndrome, Unspecified" (1 trials). Many other conditions were trialed in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" are "Drug" (15 trials), "Device" (2 trials), "Other" (2 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "ZX008 (Fenfluramine Hydrochloride)" (2 trials), "ARA-C" (1 trials), "ASCT" (1 trials) and "Acetylcarnitine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Fatebenefratelli e Oftalmico" are 17 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Fatebenefratelli e Oftalmico". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Azienda Ospedaliera Fatebenefratelli e Oftalmico, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Fatebenefratelli e Oftalmico, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".